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BACKGROUND AND PURPOSE
There are conflicting data regarding whether netrin-1 retards or accelerates atherosclerosis progression, as it can lead either to
monocyte repulsion from or retention within plaques depending on its cellular source. We investigated the effect of aspirin,
which is widely used in cardiovascular prophylaxis, on the synthesis of different isoforms of netrin-1 by endothelial cells under
pro-inflammatory conditions, and defined the net effect of aspirin-dependent systemic modulation of netrin-1 on
atherosclerosis progression.
EXPERIMENTAL APPROACH
Netrin-1 synthesis was studied in vitro using human endothelial cells stimulated with TNF-α, with or without aspirin treatment.
In vivo experiments were conducted in ApoE−/− mice fed with a high-fat diet (HFD), receiving either aspirin or clopidogrel.
KEY RESULTS
TNF-α-induced NF-κB activation up-regulated the nuclear isoform of netrin-1, while simultaneously reducing secreted netrin-1.
Down-regulation of the secreted isoform compromised the chemorepellent action of the endothelium against monocyte
chemotaxis. Aspirin counteracted TNF-α-mediated effects on netrin-1 synthesis by endothelial cells through COX-dependent
inhibition of NF-κB and concomitant histone hyperacetylation. Administration of aspirin to ApoE−/− mice on HFD increased
blood and arterial wall levels of netrin-1 independently of its effects on platelets, accompanied by reduced plaque size and
content of monocytes/macrophages, compared with untreated or clopidogrel-treated mice. In vivo blockade of netrin-1
enhanced monocyte plaque infiltration in aspirin-treated ApoE−/− mice.
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CONCLUSIONS AND IMPLICATIONS
Aspirin counteracts down-regulation of secreted netrin-1 induced by pro-inflammatory stimuli in endothelial cells. The
aspirin-dependent increase of netrin-1 in ApoE−/− mice exerts anti-atherogenic effects by preventing arterial accumulation of
monocytes.
Abbreviations
H3, histone 3; HAoEC, human aortic endothelial cell; HAT, histone acetyltransferase; HDAC, histone deacetylase; HFD,
high-fat diet; TSA, trichostatin A
Introduction
The neuroimmune guidance cue netrin-1 is known to affect
atheroma development through an inhibitory action on the
motility of monocytes/macrophages. The overall effect
depends on the tissue expression and cellular localization of
netrin-1 (Gerszten and Tager, 2012). Endothelial-derived
netrin-1, which is down-regulated under pro-atherogenic
conditions, prevents monocyte vascular infiltration (Ly et al.,
2005; Mirakaj et al., 2010; van Gils et al., 2013), whereas
haematopoietic netrin-1, which is enhanced by pro-
inflammatory stimuli (van Gils et al., 2012; Ramkhelawon
et al., 2014), favours the arterial accumulation of monocytes.
From a therapeutic perspective, such a divergence of effect
translates into the balance between ingress and egress of
monocytes into plaques requiring a cell-targeted approach,
because systemic modulation of netrin-1 would exert an
indiscriminate action on different cell types, resulting in
opposing effects on atherosclerosis progression.
As well as the cellular source of netrin-1, it may also be
important to distinguish between the different isoforms of
netrin-1 synthesized by cells. In tumour cells, both full-
length and truncated proteins have been found, displaying
different cellular compartmentalization and biological func-
tions. The full-length isoform is secreted, exerting its actions
in the micro-environment of the cell, whereas the truncated
isoform localizes within the nucleoplasm and promotes cell
proliferation (Delloye-Bourgeois et al., 2012; Harter et al.,
2014). Therefore, assessing both the existence and regulation
of secreted and nuclear isoforms of netrin-1 in cell types that
are crucial players in atheroma development might be of
prime importance in evaluating the net effect of therapeutic
approaches targeting netrin-1 on plaque progression.
We hypothesized that the reduction in netrin-1 observed
in endothelial cells under pro-inflammatory or pro-
atherogenic conditions, specifically relates to the secreted
isoform of the protein. We therefore aimed to define: (i) the
subcellular localization of netrin-1 in endothelial cells in
response to the pro-inflammatory cytokine TNF-α; (ii)
whether aspirin, a COX inhibitor which is widely used as an
anti-platelet agent but also exerts anti-inflammatory proper-
ties, differentially modulates endothelial synthesis of the two
distinct isoforms of netrin-1 under pro-inflammatory condi-
tions; and (iii) the net effect of aspirin treatment on netrin-1
production and atherosclerosis progression in vivo.
Methods
Detailed methods are available in the Supporting
Information.
In vitro experiments
Cells. HUVECs were isolated from fresh umbilical cords
obtained from uncomplicated deliveries following healthy
pregnancies; these were obtained from the labour ward at St
Thomas’ Hospital (London, UK), with written informed
consent from the mothers. The study was approved by the St
Thomas’ Hospital Research Ethics Committee. Human aortic
endothelial cells (HAoECs) were purchased from PromoCell,
UK.
Tables of Links
TARGETS
Enzymes
COX-1
COX-2
HDAC, histone deacetylase
HAT, histone acetyltransferase
LIGANDS
Aspirin
CCL2
Clopidogrel
Indomethacin
Salicylic acid
TNF-α
TSA, trichostatin A
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://
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Experiments with HUVECs. HUVECs were incubated over-
night with the following compounds: TNF-α (10 ng·mL−1,
Invitrogen, Paisley, UK); Bay 11-7085 (an NF-κB inhibitor;
5 μM, Calbiochem, Nottingham, UK); aspirin or salicylic acid
(0.5 mM for each; Sigma, Poole, UK); SC-560 (30 nM; Calbio-
chem); NS-398 (10 μM; Calbiochem); indomethacin (100 μM;
Sigma); and trichostatin A (TSA; 400 nM; Invitrogen).
Immunofluorescence staining was performed using rat
anti-netrin-1 (1:200; R&D System, Abingdon, UK), rabbit
anti-acetylated histone (1:400; Cell Signalling, Hitchin, UK)
and rabbit anti-p65 (1:100; Abcam, Cambridge, UK).
Transcript levels of nuclear and total netrin-1 were
assessed by real-time PCR (RT-PCR) and quantified using the
comparative Ct method (ΔΔCt).
Histone acetylation was quantified by Western blotting
using rabbit anti-acetylated H3 (acH3) or total H3 (both
1:1000; Cell Signalling) primary antibodies.
Netrin-1 in cell supernatants was measured by ELISA.
Western blotting of both cell lysates and cell supernatants
was performed with both rat anti-netrin-1 and goat anti-
netrin-1 (both 1:100; R&D System) primary antibodies.
Histone deacetylase (HDAC) and histone acetyltransferase
(HAT) activities were measured by commercially available
colorimetric assay kits (Epigentek, Caltag MedSystem, Buck-
ingham, UK).
Human CD14+CD16- monocytes were isolated by immu-
nomagnetic negative isolation (kit from Invitrogen, UK) of
peripheral blood mononuclear cells from healthy volunteers
(n = 3; 2 female and 1male; 18–40 years old) and on no regular
medication; particularly, they denied taking any medication
for at last 2 weeks before study. The study was approved by the
St Thomas’ Hospital Research Ethics Committee. Briefly, the
whole blood (30 ml) was collected in EDTA tubes and under-
went Lymphoprep gradient centrifugation.Mononuclear cells
were then isolated and underwent immunomagnetic negative
selection for CD14+CD16- monocytes (kit from Invitrogen)
according to the manufacturer’s instructions. Purity of isola-
tion, as determined by antigen expression (CD14+, CD16−,
CD3−, CD4−, CD8−, CD20−) using flow cytometry, was
85–90% in all experiments. Viability of monocytes was
assessed by Trypan Blue dye exclusion and was >95% imme-
diately after their isolation. Human monocyte migration was
assessed using a 24-multi-well Boyden chamber system (5 μm
pores; Corning, Birmingham, UK).
In vivo experiments
All animal care and experimental procedures complied with
the guidelines of the United Kingdom Home Office (PPL
70/6646; PIL 70/20776) and were approved by the local
Animal Ethical Committee. Studies involving animals are
reported in accordance with the ARRIVE guidelines for
reporting experiments involving animals (Kilkenny et al.,
2007; McGrath et al., 2010). A total of 62 animals were used
in the experiments described here.
Male ApoE−/− mice (B6.129P2–apoEtm1Unc/J; 8 weeks old;
Charles River Laboratories, Edinburgh, UK) were studied
before (baseline), and at 4 and 8 weeks after commencement
of a high-fat diet (HFD; Special Diets Services, Witham, UK).
Wild-type C57BL/6J mice (males; Charles River Laboratories,
Edinburgh, UK) were used as controls. An additional group of
ApoE−/− mice was kept on 8 week HFD and concomitant
anti-platelet therapy with aspirin (5 mg·kg−1·day−1) or clopi-
dogrel (25 mg·kg−1·day−1). Drugs were administered in drink-
ing water.
Plasma netrin-1 levels were measured at each time point
by ELISA; for this peripheral blood was drawn by cardiac punc-
ture using syringes containing heparin (10U/l) as anticoagu-
lant, from mice deeply anaesthetized with isoflurane
(terminal sample collection). The brachiocephalic artery was
collected at death. The following variables were also meas-
ured at each time point; expression of netrin-1 in the arterial
wall by immunofluorescence; phenotype of circulating
monocytes by flow cytometry; plaque burden and lipid
content by Oil Red O staining; and phenotype of monocytes/
macrophages infiltrating plaques by histological staining for
CD68 and tissue flow cytometry.
Monocyte trafficking into the brachiocephalic artery was
studied by autoradiography (Phosphorimager Screen,
Molecular Dynamics, GE HealthCare) (Swirski et al., 2007;
Kircher et al., 2008) following transfer of [111In]-labelled exog-
enous monocytes in ApoE−/− mice kept on 8 week HFD with
concomitant aspirin treatment (5 mg·kg−1·day−1). Experi-
ments were performed in the presence of netrin-1 blocking
obtained by i.v. administration of Unc5b-Fc, a netrin-1 recep-
tor, but is fused to the Fc portion of IgG and because of this
Unc5b-Fc is referred to as chimera antibody (800 μg·kg−1 body
weight; R&D Systems) (Tadagavadi et al., 2010).
Data analysis
Data are shown as means ±SEM. In vitro and in vivo results
were analysed by ANOVA, with or without repeated measures as
appropriate, with Bonferroni’s multiple comparisons test. P <
0.05 (two tailed) was taken to indicate statistical significance.
Results
The nuclear and secreted isoforms of netrin-1
are differentially regulated in endothelial cells
under pro-inflammatory conditions
TNF-α stimulation of HUVECs did not modify the total intra-
cellular content of netrin-1 compared with untreated cells
(Figure 1A). However, differences in cellular distribution of
netrin-1 were observed, in that TNF-α-treated HUVECs dis-
played increased netrin-1 expression within the nuclei
(Figure 1B), with a concomitant reduction in its cytoplasmic
level as demonstrated by a decrease in ratio of total to nuclear
immunofluorescence for netrin-1 (Figure 1C). These data
were corroborated by staining of non-permeabilized
HUVECs, which showed TNF-α-dependent down-regulation
of netrin-1 on the cell membrane (Figure 1D). ELISA of cell
supernatants confirmed a decrease in netrin-1 secretion by
HUVECs in response to TNF-α (Figure 1E).
Aspirin abolished both the over-expression of nuclear
netrin-1 and the down-regulation of cytoplasmic netrin-1
induced by TNF-α (Figure 1A–C). Immunofluorescence stain-
ing of non-permeabilized HUVECs similarly showed that
aspirin restored the expression of netrin-1 on the extracellu-
lar surface of TNF-α-treated cells (Figure 1D); and ELISA of
HUVEC supernatants confirmed that aspirin counteracted
the decrease in secretion of netrin-1 induced by TNF-α
(Figure 1E). We also examined the effect of other COX
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Figure 1
Cellular distribution of netrin-1 in HUVECs. Corrected total (A) and nuclear (B) cell fluorescence of netrin-1 [corrected total cell fluorescence (CTCF)
and corrected nuclear cell fluorescence (CNCF), respectively] in HUVECs following different treatments as indicated. The ratio of CTCF to CNCF
is also displayed (C). Panel (D) shows representative micrographs (20× magnification fields) of netrin-1 staining (in red) in non-permeabilized (left)
and permeabilized (right) HUVECs under the different experimental conditions as specified (scale bars = 10 μm). Netrin-1 fluorescent images were
merged with corresponding fluorescent nuclear staining with Hoechst (in blue). Pink colour within the nuclei in permeabilized cells derives from
the overlay of netrin-1 signal (red) with nuclear staining (blue), and is indicative of nuclear netrin-1 localization. Concentration of the
full-length/secreted isoform of netrin-1 was measured in cell supernatants and is displayed in (E). (F) and (G) report the levels of PGE2 and TxB2,
respectively, in HUVEC supernatant following different treatments. n = 3–7. ASA: aspirin, 0.5 mM; SC-560, 30 nM; Indom: indomethacin, 100 μM;
NS-398, 10 μM; SA: salicylic acid, 0.5 mM; TSA, 400 nM; TNF-α, 10 ng·mL–1. *P < 0.05 versus CTR (control HUVECs not treated with TNF-α).
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inhibitors such as the selective COX-1 inhibitor SC-560, the
selective COX-2 inhibitor NS-398 and the non-selective COX
inhibitor indomethacin. Only indomethacin treatment
reproduced the effects of aspirin on netrin-1 synthesis
(Figure 1). The inhibitory action exerted by these different
compounds on COX enzymic activity was measured by evalu-
ation of prostanoid release into HUVEC supernatants. ELISA
assays for TxB2 (the stable metabolite of TxA2) and PGE2
showed an increase in both prostanoids in response to TNF-α
(Figure 1F–G). Aspirin, and indomethacin to a similar extent,
reduced the synthesis of both PGE2 and TxB2 in both
untreated and TNF-α-treated cells. NS-398 suppressed PGE2
production only, either in the absence or presence of TNF-α;
while SC-560 was as effective as aspirin in suppressing TxB2
synthesis in the absence of TNF-α, but had only a minor
inhibitory action on the release of both TxB2 and PGE2 in the
presence of TNF-α (Figure 1F–G). These data demonstrated
that aspirin restored netrin-1 production in cells stimulated
with TNF-α, to baseline levels, and that this effect was COX-
dependent. However, only the combined inhibition of
COX-1 and COX-2, as obtained in response to aspirin and
indomethacin, was able to counteract the effect of TNF-α on
levels of secreted and nuclear netrin-1.
We also found that the HDAC inhibitor TSA similarly
counteracted the effect of TNF-α on netrin-1 production
(Figure 1), although through a COX-independent mecha-
nism as discussed below.
The expression of netrin-1 was next characterized by
Western blotting of cell lysates and supernatants in order to
investigate whether different isoforms of netrin-1, with dis-
tinct cellular distributions, were synthesized by HUVECs,
as has previously been reported for tumour cells
(Delloye-Bourgeois et al., 2012). Using the rat anti-netrin-1
antibody that was used for the ELISA assays and immunofluo-
rescence staining described above, two isoforms were
detected in cell supernatants, at 55 kDa and around 70 kDa
(Supporting Information Fig. S1a). The same antibody only
detected a 55 kDa protein in cell lysates (Supporting Infor-
mation Fig. S1b). A goat anti-netrin-1 antibody specifically
targeting the C-terminal of the protein, which was previously
shown to contain the nuclear localization signal of netrin-1
(Delloye-Bourgeois et al., 2012), only detected a 55 kDa
protein in both cell lysates and cell supernatants (Supporting
Information Fig. S1a,b). These data suggest that the HUVECs
were able to synthesize a truncated isoform of netrin-1 that
was predominantly contained within cells and, given the
presence of the C-terminal nuclear signal, could localize
within the nuclei; whereas the full-length isoform of netrin-1,
which lacks the C-terminal nuclear signal, was secreted, as
did the truncated isoform to a much lesser degree.
Differential gene regulation of secreted and
nuclear netrin-1 in endothelial cells
Because gene induction of netrin-1 has been demonstrated to
be under transcriptional control by NF-κB (Paradisi et al.,
2008), we sought to evaluate whether activation of NF-κB in
TNF-α-treated HUVECs gives rise to differential gene induc-
tion of the two isoforms of netrin-1. As expected, TNF-α
treatment induced p65 nuclear translocation, consistent with
NF-κB activation (Figure 2A,B). By quantitative RT-PCR using
primers that nonselectively amplify both the nuclear (trun-
cated) and secreted (full-length) isoforms of netrin-1, TNF-α
was found to induce total netrin-1 gene transcription
(Figure 2C). However, amplification of netrin-1 mRNA using
primers that selectively recognize the full-length (secreted)
isoform of the protein showed that TNF-α does not signifi-
cantly modify its gene induction (Figure 2D), and in fact the
ratio of secreted to total netrin-1 transcripts (Figure 2E)
exhibited a trend towards reduction in response to TNF-α.
These data demonstrate that TNF-α-dependent NF-κB activa-
tion gives rise to up-regulation specifically of the nuclear
(truncated) isoform of netrin-1. Consistent with this, inhibi-
tion of NF-κB in TNF-α-treated HUVECs, by co-incubation
with Bay 11-7085, also reduced the TNF-α-induced over-
expression of netrin-1, as revealed by using primers that
amplify both isoforms (Figure 2C), while it did not affect the
gene transcription of full-length netrin-1 nor the ratio of
secreted to total netrin-1 compared with cells treated with
TNF-α only (Figure 2D,E). At the protein level, Bay 11-7085
restored the generation of secreted netrin-1 to baseline levels
in TNF-α-stimulated HUVECs, as evaluated by cellular immu-
nofluorescence staining and ELISA of cell supernatants, while
at the same time suppressing the expression of nuclear
netrin-1 induced by TNF-α (Figure 2F–G).
▶
Figure 2
NF-κB activation and gene induction of truncated (nuclear) and full-length (secreted) isoforms of netrin-1. (A) Representative micrographs (20×
magnification fields) of p65 staining under the different experimental conditions as indicated. p65 fluorescent images (in green) were merged with
corresponding fluorescent nuclear staining with Hoechst (in blue). Yellow colour within the nuclei derives from the overlay of p65 signal (green)
with nuclear staining (blue), and is indicative of nuclear p65 localization. p65 nuclear translocation was taken as an index of NF-κB activation and
is reported in (B) as percentage of nuclei expressing p65 under the different experimental conditions. Panels (C) and (D) show accumulated data
for quantitative RT-PCR for netrin-1 (NTN-1) using primers for (C) total netrin-1 (comprising both the full-length and truncated isoforms) or (D)
the full-length/secreted isoform specifically, both normalized to the housekeeping gene GAPDH. The ratio of the two isoforms was obtained by
normalizing the full-length isoform of netrin-1 to total netrin-1 (E). Data are reported as fold changes compared with control (untreated cells,
dotted blue line). n = 3–5. Panels (F) and (G) show representative micrographs (20× magnification fields) of netrin-1 staining (in red) in
permeabilized (F) and non-permeabilized (G) HUVECs either untreated (control) or TNF-α treated, either in the presence or absence of the NF-κB
inhibitor Bay 11-7085 (BAY), as specified. Netrin-1 fluorescent images were merged with corresponding fluorescent nuclear staining with Hoechst
(in blue). Pink colour within the nuclei in permeabilized cells (F) derives from the overlay of netrin-1 signal (red) with nuclear staining (blue), and
is indicative of nuclear netrin-1 localization. In permeabilized cells (F), corrected total and nuclear cell fluorescence of netrin-1 (CTCF and CNCF,
respectively) following different treatments was calculated and reported in the corresponding graphs. The ratio of CTCF to CNCF is also displayed.
Secreted netrin-1 was measured by ELISA in cell supernatants and results are reported in (G). n = 3. Scale bars = 10 μm. ASA: aspirin, 0.5 mM;
SC-560, 30 nM; Indom: indomethacin, 100 μM; NS-398, 10 μM; TSA, 400 nM; TNF-α, 10 ng·mL−1; Bay 11-7085, 5 μM. *P < 0.05 versus CTR
(control HUVECs not treated with TNF-α).
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Quantitative RT-PCR demonstrated that none of the COX
inhibitors tested in our study affected TNF-α-induced gene
transcription of total netrin-1 in HUVECs (Figure 2C).
However, aspirin and indomethacin specifically enhanced
the mRNA level of the secreted isoform of netrin-1
(Figure 2D), as well as the ratio of secreted to total netrin-1
(Figure 2E). By immunofluorescence staining of HUVECs, we
found that both aspirin and indomethacin abolished (and
SC-560 significantly reduced, although to a much lesser
extent than aspirin or indomethacin) the TNF-α-dependent
p65 nuclear translocation (Figure 2A,B). Selective inhibition
of either COX isoform alone was less effective than aspirin in
abolishing NF-κB activation. We also found that inhibition of
p65 nuclear translocation in response to TNF-α was strongly
inhibited by TSA (Figure 2A,B), which also specifically
enhanced the mRNA synthesis of secreted netrin-1 as dem-
onstrated by quantitative RT-PCR (Figure 2C–E).
Aspirin regulation of secreted netrin-1 occurs
through epigenetic modification
The above experiments demonstrate that, although NF-κB
activation gives rise to gene induction and consequent over-
expression of nuclear netrin-1, the synthesis of secreted
netrin-1 is regulated in a different way. In accordance with
this hypothesis, it has previously been reported that the two
isoforms have different promoters (Delloye-Bourgeois et al.,
2012). Because epigenetic modification of chromatin and
DNA is considered a crucial regulator of gene expression in
the TNF-α-mediated inflammatory response (Barnes et al.,
2009; Pons et al., 2009; McKinsey, 2012), we postulated that
modulation of histone H3 acetylation, which has a key role in
vascular inflammation and atherosclerosis (Zampetaki et al.,
2010), could be involved in the differential gene induction of
secreted and nuclear netrin-1 under the different experimen-
tal conditions. Western blotting and immunofluorescence
staining demonstrated that treatment of HUVECs with TNF-α
did not alter the level of acetylated H3 (Figure 3A–C).
Co-stimulation of HUVECs with TNF-α and the NF-κB
inhibitor Bay 11-7085 also did not modify the level of acety-
lated H3 compared with untreated cells (Figure 3B). However,
in the presence of aspirin, TNF-α-treated cells displayed
higher expression of acetylated H3 compared with control
cells (Figure 3A–C). These results were reproduced by
co-incubating HUVECs with TNF-α and salicylic acid. Aspirin
alone did not affect acetylated H3 (Figure 3A).
The HDAC inhibitor TSA, which was used as a positive
control to increase H3 acetylation and which increased acety-
lated H3 up to five times more than the level induced by
aspirin or salicylic acid (Figure 3A–C), was also able not only
to restore but even increase the secretion of netrin-1 into the
supernatant of cells co-treated with TNF-α (Figure 1E).
Moreover, TSA alone enhanced the secretion of netrin-1 by
HUVECs even in the absence of TNF-α (Figure 1E). TSA treat-
ment also suppressed TNF-α-dependent NF-κB activation
(Figure 2A,B), thus reducing the level of netrin-1 within the
nuclei (Figure 1A), and induced gene transcription of the
secreted isoform of netrin-1 (Figure 2C–E).
In order to further investigate the biomolecular mecha-
nism underlying aspirin/salicylate-mediated increase in
acetylated H3 in HUVECs stimulated with TNF-α, we assessed
the enzymic activity of HAT and HDAC in nuclear extracts.
We found that aspirin, and salicylic acid to a similar extent,
increased HAT (Figure 3D) and partly inhibited HDAC
(Figure 3E) activities in TNF-α-treated cells, thus resulting in a
marked reduction of the HDAC/HAT ratio compared with
control or TNF-α-stimulated HUVECs (Figure 3F). These
effects appeared to be partly mediated by a direct action of
these compounds on the enzymic activity of HAT; indeed,
addition of either salicylic acid or aspirin to nuclear extracts
isolated from untreated cells led to enhanced HAT activity
(Figure 3G). On the other hand, inhibition of HDAC activity
is likely to be indirectly mediated, as neither aspirin nor
salicylic acid was able to directly modify the HDAC activity of
isolated nuclear extracts (Figure 3H).
Aspirin-dependent increase of
endothelial-derived netrin-1 reduces
monocyte chemotaxis
We next explored the hypothesis that the aspirin-dependent
increase in endothelium-derived netrin-1 in TNF-α-
stimulated cells would result in a chemorepellent action on
arterial infiltration by monocytes. Our migration assays
showed that TNF-α enhanced the monocyte chemotaxis
towards activated human aortic endothelial cells (HAoECs)
compared with unstimulated cells. Aspirin pretreatment of
HAoECs significantly reduced monocyte migration towards
TNF-α-stimulated cells, this effect being abolished by
co-incubation with UNC5b-Fc (Figure 4A–C), which neutral-
izes soluble netrin-1 and reduces its bioactivity, as previously
described (van Gils et al., 2013). Similar to the effect observed
in HUVECs, aspirin counteracted the up-regulation of nuclear
netrin-1 and the reduction in the secreted isoform of netrin-1
in response to TNF-α in HAoECs (Supporting Information
Fig. S2). Co-staining of HAoECs for netrin-1 and p65 under
the different experimental conditions showed that nuclear
netrin-1 up-regulation in TNF-α-treated cells was paralleled
by p65 nuclear translocation, indicative of NF-κB activation.
As observed in HUVECs, aspirin inhibited TNF-α-dependent
NF-κB activation in HAoECs (Supporting Information
Fig. S2a,b).
Because monocytes are known to be capable of synthesiz-
ing netrin-1 (van Gils et al., 2012), we tested the possibility
that aspirin exerts a direct effect on monocyte motility by
enhancing their own production of secreted netrin-1. We
found that monocytes pretreated with aspirin displayed
reduced motility towards the chemokine CCL2 compared
with untreated cells, this effect being similar to that exerted
by recombinant human netrin-1, and again this was abol-
ished by UNC5b-Fc (Figure 4D–F).
Aspirin enhances systemic and vascular
expression of netrin-1 in ApoE−/− mice
The in vitro experiments decribed above suggest that aspirin
might be able to enhance the expression of netrin-1 at a
systemic level by acting on both the vascular endothelium
and monocytes. In order to test whether such an effect is
observable in vivo, as well as the resultant net effect on ath-
erosclerosis progression, we treated ApoE−/− mice fed with a
HFD with aspirin. Considering that platelet inhibition itself
might have important anti-inflammatory effects, a separate
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group of animals was treated with a different anti-platelet
drug, clopidogrel, working through an unrelated mechanism
(P2Y12 receptor inhibition).
Administration of aspirin to ApoE−/− mice given 8 weeks
of HFD induced a significant increase in plasma netrin-1
compared with levels measured in both untreated and
clopidogrel-treated animals (Figure 5A). The up-regulation of
netrin-1 in the aspirin-treated group was also evident within
the arterial wall, as demonstrated by immunofluorescence of
the abdominal aorta (Figure 5B,C). No atherosclerotic lesions
were detectable in the abdominal aortas of HFD-fed ApoE−/−
mice, either with or without anti-platelet treatment, in
contrast to the abundance of plaque observed in the brachio-
cephalic arteries of these same animals (Figure 6). Neverthe-
less, netrin-1 was expressed in the abdominal aortas and
co-localized with the endothelial cell marker CD31
(Figure 5C). Aspirin, but not clopidogrel, increased the
expression of endothelial netrin-1 within the arterial wall,
compared with that in untreated animals (Figure 5B,C).
HDAC activity, as measured in nuclear extracts, was lower in
the aortic wall of both aspirin- and clopidogrel-treated
animals than control animals (Figure 5D), while aortic HAT
activity was higher in the aspirin-treated mice only
(Figure 5E). As a consequence, both anti-platelet drugs
reduced the HDAC/HAT ratio, although aspirin treatment did
so to a greater extent than clopidogrel (Figure 5F).
Figure 3
Histone 3 acetylation and netrin-1 expression in HUVECs. Western blotting (A, B) and immunofluorescence (C) studies showing degree of histone
acetylation in HUVECs in response to different treatments as specified. In the Western blots, densitometric analysis of acetylated H3 (acH3) was
normalized to total H3. In immunofluorescence experiments, the corrected nuclear cell fluorescence (CNCF) was calculated (C). Panels (D)–(H)
show the effect of aspirin (ASA) on HAT and HDAC activities in HUVECs. HAT (D) and HDAC (E) activities, and HDAC/HAT ratio (F), were measured
in nuclear extracts isolated from HUVECs following treatments as specified. Nuclear extracts were isolated from HUVECs not stimulated with
TNF-α, and HAT (G) and HDAC (H) activities were tested in the presence of either ASA or salicylic acid. n = 3. ASA, 0.5 mM; SC-560, 30 nM; SA:
salicylic acid, 0.5 mM; Indom: indomethacin, 100 μM; TSA, 400 nM; TNF-α, 10 ng·mL−1; Bay 11-7085 (BAY), 5 μM. *P < 0.05 versus CTR (control
HUVECs not treated with TNF-α).
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ApoE−/− mice on HFD, either untreated or treated with
these anti-platelet drugs, developed atherosclerotic plaques in
the brachiocephalic arteries. However, treatment with aspirin
reduced the total plaque area compared with control animals
(Figure 6A–C). By contrast, clopidogrel had no detectable
effect on plaque extent (Figure 6A–C). Moreover, plaques in
mice receiving aspirin, but not clopidogrel, displayed a reduc-
tion in lipid content, as evaluated by the area stained with
Oil-Red O (Figure 6A–C), as well as in myeloid cell content, as
determined by CD68 staining (Figure 6B). Suppression of
infiltration of atherosclerotic lesions by inflammatory cells
in the aspirin group was confirmed by tissue flow cytometry
to specifically assess the content of different subsets of
monocytes/macrophages. Indeed, the brachiocephalic arter-
ies obtained from ApoE−/− mice treated with aspirin, but not
clopidogrel, exhibited less total myeloid cell infiltration com-
pared with untreated animals, with a reduction in both the
monocyte (F4/80low) and macrophage (F4/80high) components
(Figure 6D). Within the monocytic population, aspirin was
able to suppress vascular infiltration by both Ly6Chigh and
Ly6Clow subtypes (Figure 6F). Clopidogrel exerted a weaker
action than aspirin on monocyte arterial infiltration
(Figure 6D), specifically reducing the content of Ly6Clow cells
only (Figure 6F), thus leading to a slight modulation of the
prevalence between the two monocyte subpopulations
within the arterial wall compared with untreated animals,
with predominance of Ly6Chigh over Ly6Clow cells in the
clopidogrel group (Figure 6F). Plaques from untreated or
clopidogrel-treated mice exhibited a similar content of both
Ly6Chigh monocytes (Figure 6F) and macrophages (Figure 6D).
Anti-platelet therapy abolishes
atherosclerosis-related blood monocytosis
We next evaluated whether the reduced monocyte/
macrophage plaque content in aspirin-treated animals was
related to a systemic anti-inflammatory action of the drug on
peripheral monocyte count and phenotype. In accordance
with previous reports, we found a time-dependent expansion
of total monocytes in the peripheral blood of ApoE−/− mice fed
with a HFD over the 8 week period of study (Figure 7A,C). The
predominant subtype in the blood was Ly6Chigh throughout
the study period (Figure 7A,F), although the count and per-
centage of Ly6Clow monocytes also increased over time
(Figure 7A,F). The increase in Ly6Chigh monocytes was attrib-
utable to the HFD regime, because a similar expansion of this
particular subset of monocytes was observed in C57BL/6J
animals fed with a HFD (Supporting Information Fig. S3a),
even in the absence of atherosclerosis development. ApoE−/−
mice, but not the wild-type strain, developed a concomitant
progressive increase in circulating Ly6Clow monocytes (Sup-
porting Information Fig. S3b) and, in agreement with previ-
ous findings (Potteaux et al., 2011), their percentage was
strongly and directly related to plaque size in the brachioce-
phalic artery. Conversely, the level of Ly6Chigh was inversely
related to lesion area, and no relationship was found between
total monocytes and plaque area (Supporting Information
Fig. S3c–e).
Atherosclerosis-related total monocytosis in ApoE−/− mice
at the end of the 8 week HFD regimen was significantly
reduced by concomitant treatment with either clopidogrel or
aspirin (Figure 7B–D,H). The distribution pattern of the dif-
ferent monocytic subsets was also modulated by anti-platelet
treatment, as the progressive increase in percentage and
count of Ly6Clow over Ly6Chigh cells was attenuated by both
anti-platelet therapies, although not to baseline values
(Figure 7F). Measurement of P-selectin-expressing platelets, as
a marker of in vivo platelet activation, showed that both
aspirin and clopidogrel inhibited the platelet P-selectin
expression in ApoE−/− mice on HFD, clopidogrel doing so to a
greater extent than aspirin (Figure 7E).
Aspirin reduces monocyte trafficking within
atherosclerotic lesions through modulation of
systemic netrin-1
The results described above suggested that the greater action
of aspirin over clopidogrel on atherosclerotic plaque size and
composition in ApoE−/− mice fed with a HFD was independent
of its inhibitory effect on platelet activity and consequent
suppression of blood monocytosis, as a similar modulation of
these parameters was exerted by clopidogrel (Figure 7A–F).
Because we observed that the two anti-platelet drugs differed
substantially in their ability to regulate systemic and vascular
endothelial expression of netrin-1 (Figure 6), we postulated
that aspirin-mediated suppression of monocyte arterial accu-
mulation could be mediated through its effects on netrin-1.
In order to test this, we examined adoptively transferred
monocyte trafficking in the brachiocephalic artery of ApoE−/−
mice fed with a HFD and co-treated with aspirin for 8 weeks
in vivo, either in the presence or absence of netrin-1 blockade
using Unc5b-Fc chimera antibody or isotype control respec-
tively. Atherosclerotic vessels of aspirin-treated ApoE−/− mice,
harvested 36 h after injection of exogenous radiolabelled
Figure 4
Effect of aspirin (ASA) on migration of human CD14+CD16− monocytes. Migration of human CD14+CD16− monocytes towards a monolayer of
HAoECs (A–C) or towards an CCL2 (100 ng·mL−1) gradient (D–F) is shown under different experimental conditions, as indicated in the graphs.
When tested against an HAoEC monolayer, the endothelial cells, but not monocytes, were pretreated with ASA, and migration was conducted in
the presence or absence of Unc5b-Fc. When tested towards a CCL2 gradient, monocytes were pretreated with ASA and migration was performed
either in the presence or absence of Unc5b-Fc. (A) and (D) show cell count under light microscopy in five microscopic fields (20× magnification)
on the lower surface of the membranes of the Boyden chambers, following removal of non-migrated cells on the upper surface. (B) and (E) show
count, as determined by flow cytometry, of monocytes (CD14+ cells, gated) which have migrated to the lower well of the Boyden chamber system,
with representative dot plots also displayed (C and F). n = 3. CTR: TNF-α-stimulated HAoECs (C) or untreated monocytes (F); ASA: ASA-treated
HAoECs (C) or monocytes (F); ASA + Unc5b-Fc: following ASA pretreatment of either HAoECs (C) or monocytes (F). Unc5b-Fc was added during
monocyte migration. Histograms show count of migrated monocytes in CTR (grey), ASA (blue) and ASA + Unc5b-Fc (red). *P < 0.05 versus ASA;
†P < 0.01 versus netrin-1.
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monocytes and assessed by autoradiography, exhibited an
increase in monocyte accumulation in those receiving the
netrin-1 blocking antibody compared with those receiving
the isotype control (Figure 7G).
Discussion and conclusions
Aspirin and clopidogrel are widely used for cardiovascular
prophylaxis. Our demonstration that both drugs suppressed
the blood monocytosis that accompanies atheroma develop-
ment in ApoE−/− mice provides good evidence for a systemic
anti-inflammatory effect of both anti-platelet drugs.
However, the fact that only aspirin was able to reduce plaque
size and inflammation suggests that this drug exerts benefi-
cial effects on atherogenesis over and above its anti-platelet
action. Our data both in vitro and in vivo suggest an important
role in this regard for netrin-1 modulation, whose
up-regulation by aspirin at a systemic level leads to reduced
arterial accumulation of monocytes.
Aspirin-dependent down-regulation of several endothe-
lial molecules involved in monocyte trafficking within the
atheroma has been demonstrated previously (Weber et al.,
1995; Pierce et al., 1996; Dunoyer-Geindre et al., 2004; Yang
et al., 2004). However, our data showing a modulatory activ-
ity of aspirin on endothelial-derived netrin-1 and the key role
of secreted netrin-1 in preventing monocyte vascular recruit-
ment are entirely novel. In vitro, we found that the sole
blockade of netrin-1 was able to entirely abolish the mono-
cyte chemorepellent action of activated endothelial cells
induced by aspirin, irrespective of any potential effect of the
drug on other endothelial-derived adhesive/chemotactic
molecules. Similarly, our in vivo experiments of adoptively
transferred monocytes in ApoE−/− mice demonstrated that
inhibition of netrin-1 enhances monocyte trafficking into
atherosclerotic lesions in aspirin-treated animals. Moreover,
we found that up-regulation of netrin-1 during atherosclero-
sis development, in response to aspirin treatment, was not
detrimental for plaque progression, but rather beneficial and
was associated with a reduction in the inflammatory compo-
nent of lesions (comprising both monocyte and macrophage
content) that was not observable with clopidogrel treatment.
In accordance with our findings, it has previously been
reported that plaque development can be delayed in a murine
model of atherosclerosis by netrin-1 gene therapy (Khan
et al., 2011). On the other hand, van Gils et al. (2012) pro-
posed selective down-regulation of haematopoietic netrin-1
as a strategy to favour monocyte/macrophage egress from
plaques, with a consequent putative beneficial effect on ath-
eroma development. Such a strategy may certainly be rel-
evant in the later stages of disease, where large numbers of
myeloid cells have already accumulated in the plaque.
However, the evidence from the present study suggests that,
at least in the earlier stages of atherosclerosis, enhancement
of vascular netrin-1 expression (reportedly down-regulated
under pro-atherogenic conditions; van Gils et al., 2013) may
prevent monocyte infiltration and macrophage accumulation
in nascent plaques and hence reduce their size and lipid
content. As Ly6Chigh monocytes appear to be the main pre-
cursors of plaque macrophages (Swirski et al., 2007), it is
likely that the ability of aspirin to decrease atherosclerosis
progression is primarily due to its negative modulatory action
on arterial accumulation of this particular subset of cells.
Indeed, clopidogrel, which also reduced the Ly6Clow but not
the Ly6Chigh cell component in plaques, albeit with less effi-
cacy than aspirin, did not exert any beneficial effect on
plaque size, macrophage or lipid content.
As discussed above, aspirin is known to modulate the
endothelial expression of adhesion molecules. We have not
investigated this here and so cannot exclude the possibility
that arterial infiltration of monocytes may have been affected
by a concomitant pharmacological action of aspirin on
endothelial-derived molecules other than netrin-1. Having
said that, clopidogrel also exerts anti-inflammatory proper-
ties on the vasculature (Li et al., 2007; Hoving et al., 2011),
but in our study clopidogrel was less effective than aspirin in
reducing the monocyte/macrophage component of arterial
lesions.
Our data also provide entirely novel insights on the
mechanism(s) by which aspirin regulates endothelial
netrin-1. We have demonstrated that two different isoforms
of netrin-1, full length and truncated, were expressed by the
vascular endothelium, and that these exhibited important
differences in their gene regulation under either physiological
or pro-inflammatory conditions. Specifically, we demon-
strated that TNF-α modified the balance between the two
isoforms of netrin-1, in terms of both gene expression and
protein production, leading to NF-κB-dependent preferential
transcription of truncated netrin-1 over full-length netrin-1,
with consequent over-expression of the protein within nuclei
and concomitant reduction in the synthesis of secreted
netrin-1. The NF-κB inhibitor Bay 11-6075 reduced the TNF-
Figure 5
Aspirin (ASA) increases systemic and vascular expression of netrin-1 in ApoE−/− mice. (A) ELISA of netrin-1 in plasma, from ApoE−/− mice on 8 week
HFD, either untreated (8 weeks; n = 8) or treated with ASA (5 mg·kg−1·day−1; n = 8) or clopidogrel (Clop; 25 mg·kg−1·day−1; n = 8). Also shown
in (A) are plasma netrin-1 levels in ApoE−/− mice after 4 weeks of HFD (4 weeks; n = 4) for comparison. (B–C) The micrographs show
immunofluorescence staining for netrin-1 (red), the endothelial marker CD31 (green) and nuclei by DAPI (blue) of aortas from ApoE−/− mice after
8 week HFD either untreated (left) or ASA treated (right, ASA 5 mg·kg−1·day−1); magnification = 20× (scale bars = 50 μm). Bottom panels show
merging of the three stainings: the white arrows indicate the luminal localization of netrin-1 (red) within the arterial wall and its co-localization
with the endothelial cell marker CD31 (green), which is evident in the ASA-treated group but not in either clopidogrel-treated or untreated mice.
The graph reports quantification of mean fluorescence intensity for netrin-1 and CD31 in the different groups as specified, and it is reported as
fold change versus control (untreated) animals. (D) and (E) report HDAC and HAT activities measured in nuclear extracts isolated from the aortic
arterial wall of ApoE−/− mice at the end of the 8 week HFD period, either untreated (8 weeks) or treated with ASA (5 mg·kg−1·day−1) or clopidogrel
(25 mg·kg−1·day−1). Also shown in (F) is the HDAC/HAT ratio in the different groups. Data for (A) are shown as median ± interquartile ranges.
*P < 0.05 versus 8 weeks.
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α-dependent over-expression of nuclear netrin-1 and restored
the balance between the two isoforms, both in terms of tran-
script level and protein production. Aspirin, salicylic acid,
indomethacin and TSA were all able to prevent the nuclear
netrin-1 increase induced by TNF-α, attributable to their
ability to suppress NF-κB activation and consequent gene
transcription of the truncated protein. However, these com-
pounds also directly modified the level of secreted netrin-1,
although to different extents. Unlike the NF-κB-dependent
transcription of the nuclear isoform, we found that gene
induction of full-length secreted netrin-1 was NF-κB inde-
pendent and that that chromatin remodelling, as caused by
increased histone acetylation in aspirin/salicylic acid or TSA-
treated cells, enhanced its synthesis at the transcriptional
level. The COX inhibition exerted by aspirin is likely to be
responsible as indomethacin exerted a similar action to
aspirin in terms of NF-κB inhibition, histone acetylation and
netrin-1 release into HUVEC supernatant. The action of TSA,
an HDAC inhibitor, on netrin-1 was entirely COX independ-
ent. Although we found that TSA reduced PGE2 synthesis in
response to TNF-α treatment, such an effect was most likely
because of the NF-κB inhibitory action of TSA in TNF-α-
treated cells, with consequent suppression of the NF-κB-
dependent gene induction of COX-2. Of note, unlike aspirin,
TSA increased the production of full-length netrin-1 in
endothelial cells either in the presence or absence of TNF-α,
most likely because of the extent of H3 acetylation that was
considerably higher, compared with that observed in aspirin
or salicylic acid-treated HUVECs. This resulted in a level of
gene transcription of the secreted isoform of netrin-1 that was
40 times higher than untreated cells, more than 10 times the
increase observed with aspirin or indomethacin. The rel-
evance of histone acetylation in the context of atherosclerosis
has been previously reported, such that TSA retards athero-
sclerosis development (Zampetaki et al., 2010; Zhou et al.,
2011) by acting on endothelial function (Inoue et al., 2006;
Wang et al., 2007). It is known that histone acetylation
enables access to genes by transcription factors. Our data
suggest that aspirin alters the balance between histone acety-
lation and deacetylation in favour of the former, thereby
promoting transcription of full-length netrin-1 in TNF-α-
treated cells.
The fact that aspirin alone was not able to induce any
significant change in the level of netrin-1 and of acetylated
H3, compared with untreated cells is highly suggestive of a
concerted action of TNF-α and aspirin co-treatment on both
these events. In keeping with this, our study of HAT and
HDAC activities revealed that aspirin augmented the increase
in HAT activity induced by TNF-α alone, most likely because
of a direct effect on HAT activity as demonstrated in nuclear
extracts. The simultaneous suppression of HDAC, albeit
through an indirect action of aspirin on the enzyme, resulted
in an imbalance between histone acetylation and deacetyla-
tion. In our in vivo model, study of HAT and HDAC activities
showed that systemic inflammation, and particularly platelet
activity, was crucial in determining the status of histone
acetylation within the arterial wall. Although acting through
different pharmacological mechanisms, the anti-platelet
effect exerted by clopidogrel or aspirin was associated with
roughly equal attenuation of arterial HDAC activity, thus
demonstrating the crucial role played by platelet activation
on this parameter. However, the concomitant increase in HAT
activity exerted by aspirin was not seen in clopidogrel-treated
animals, thereby giving rise to a significant modification of
the HDAC/HAT ratio only in the group of mice treated with
aspirin. In support of our in vitro data showing the relevance
of histone acetylation to secreted netrin-1 synthesis, we
observed that blood and endothelial netrin-1 levels were
increased in aspirin- but not clopidogrel-treated animals
in vivo.
In conclusion, we have provided evidence for selective
and differential regulation of the secreted and nuclear iso-
forms of netrin-1 in endothelial cells. The suppression of
endothelial-derived netrin-1 under pro-inflammatory condi-
tions only relates to the secreted isoform of the protein, with
consequent enhancement of arterial infiltration by mono-
cytes. Aspirin increases netrin-1 synthesis by the vascular
endothelium. This effect, which was COX dependent, was
Figure 6
Effect of aspirin (ASA) and clopidogrel on monocyte/macrophage plaque content. (A, B) Representative pictures of Oil Red O(ORO) (A) and CD68
(B) staining of cryosections of the brachiocephalic artery (BA) of ApoE−/− mice at the end of 8 week HFD in clopidogrel (25 mg·kg−1·day−1) or
ASA-treated animals (ASA: 5 mg·kg−1·day−1) as indicated (magnification 20× and 40× on the left and right sides of each panel respectively).
Counterstaining was with haematoxylin. Black arrows indicate the atherosclerotic lesion detected on histological section. Total and ORO-positive
area of plaques under the different experimental conditions is reported in (C) (scale bars = 150 μm lower power; 50 μm higher power). (D) Total
myeloid cell count [F4/80+ CD115+ Lin- (B220, CD90, Ly6G, NK1.1)], number of monocytes [F4/80low CD115+ Lin- (B220, CD90, Ly6G, NK1.1)]
and macrophages [F4/80high CD115+ Lin- (B220, CD90, Ly6G, NK1.1)] within the BA in untreated animals (8 weeks; n = 6) and those treated with
either clopidogrel (25 mg·kg−1·day−1; n = 6) or ASA (5 mg·kg−1·day−1; n = 5). Values are indicated as cell number/mg tissue. Relative prevalence
of monocytes (F4/80low cells, dark grey) and macrophages (F4/80low cells, light grey) is reported in the pie charts and expressed as percentage of
total myeloid cells [F4/80+ CD115+ Lin- (B220, CD90, Ly6G, NK1.1)]. (E) Representative flow cytometry plots showing gating strategy for
monocyte/macrophage characterization in the BA of each group of animals. Briefly, total myeloid cells were identified within the Lin− gate as
CD115+ F4/80+ cells. Within this population, monocytes (F4/80low; left quadrants in the dot plots indicating Ly6C vs. F4/80) and macrophages
(F4/80high and Ly6Clow cells; lower right quadrant in the dot plots indicating Ly6C vs. F4/80) were differentiated on the basis of intensity of
fluorescence for F4/80 staining. Total monocytic population was further distinguished into Ly6Chigh and Ly6Clow cells (bottom plots). The
percentage shown in the dot plots refers to the frequency of gated cells within the parent population. In the contour plots, the relative prevalence
of either monocytes (Lin− CD115+ F4/80low) and macrophages (Lin− CD115+ F4/80low Ly6Clow) or Ly6Chigh and Ly6Clow monocytes is shown. (F)
Ly6Chigh and Ly6Clow monocyte count within the BA in the different animal groups as indicated. Values are indicated as cell number/mg tissue. Pie
charts show accumulated data (8 weeks: n = 4; clopidogrel: n = 4; ASA: n = 5) reporting percentage of Ly6Chigh (dark grey) and Ly6Clow (light grey)
cells over total monocytes [F4/80low CD115+ Lin- (B220, CD90, Ly6G, NK1.1)] measured in the BA of each group of animals. *P < 0.05 versus 8
weeks.
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mediated by an epigenetic regulation of netrin-1 that
occurred only in the presence of a pro-inflammatory
endothelial state. As a result, aspirin preserved the synthesis
of secreted netrin-1 under pro-inflammatory conditions, thus
counteracting monocyte/macrophage plaque accumulation.
Future clinical investigations are needed to verify the appli-
cability of these findings to human atherosclerosis, as well as
to non-cardiovascular diseases including neurological disor-
ders (Rajasekharan and Kennedy, 2009; Izzi and Charron,
2011) and cancer (Delloye-Bourgeois et al., 2012; Kefeli et al.,
2012; Ko et al., 2012) where aspirin has also been reported to
exert protective actions (Algra and Rothwell, 2012; Rothwell
et al., 2012a,b).
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